Learning from clinical trials of neoadjuvant checkpoint blockade

Area of Science:

• Oncology
• Immunotherapy
• Translational Research

Background:

• Neoadjuvant checkpoint inhibition is an emerging strategy for managing resectable melanoma and other solid tumors.
• This pre-surgical therapy demonstrates high pathologic response rates, which are linked to improved survival outcomes.

Purpose of the Study:

• To discuss the rationale behind neoadjuvant immunotherapy using preclinical and translational data.
• To summarize recent clinical trial results and ongoing research in this field.
• To explore future directions for enhancing reverse translation to optimize patient outcomes.

Main Methods:

• Review of preclinical studies and human translational data.
• Analysis of results from recent clinical trials.
• Discussion of ongoing research and future strategies.

Main Results:

• Neoadjuvant immunotherapy exhibits a high pathologic response rate in clinical trials.
• Pathologic response is a significant correlate of patient survival outcomes.
• Biopsies obtained routinely facilitate understanding of therapy response and reverse translation.

Conclusions:

• Neoadjuvant immunotherapy is a promising strategy for resectable solid tumors, particularly melanoma.
• Reverse translation of clinical data is crucial for refining and personalizing future treatment strategies.
• Further research is needed to optimize neoadjuvant immunotherapy and its translational applications.